Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
IRadimed Corporation manufactures MRI-compatible medical devices, specifically IV infusion pump systems and patient vital signs monitoring equipment designed to operate safely within the magnetic field environment of MRI suites. The company holds a dominant niche position in this specialized market with its flagship MRidium 3860+ IV pump system and IRadimed 3880 MRI patient monitoring system, serving hospitals and imaging centers globally. With 77% gross margins and zero debt, IRMD operates a capital-efficient model focused on recurring disposable sales and service contracts.
IRMD operates a razor-and-blade model where capital equipment sales (IV pumps at ~$35K-40K per unit, monitors at ~$25K-30K) establish installed base, followed by recurring revenue from proprietary disposable IV sets, service contracts, and replacement parts. Pricing power stems from regulatory barriers (510(k) FDA clearance for MRI compatibility), switching costs once integrated into hospital workflows, and limited direct competition in the MRI-safe device niche. The company manufactures in Winter Springs, Florida with direct sales force targeting radiology departments and MRI suite operators.
Quarterly device unit shipments (MRidium pumps and IRadimed monitors) - proxy for hospital capital spending on MRI infrastructure
Installed base growth and recurring disposables attach rates - indicates customer retention and utilization intensity
New hospital MRI suite installations and upgrades to 3T/7T systems requiring compatible equipment
FDA clearances for product enhancements or new MRI-compatible devices expanding addressable market
International expansion progress, particularly in Europe and Asia-Pacific where MRI adoption is accelerating
Technological obsolescence if competitors develop superior MRI-compatible devices or if MRI technology shifts render current products incompatible (e.g., ultra-high-field 10T+ systems)
Regulatory risk from FDA reclassification or heightened safety standards for MRI-compatible devices requiring costly re-engineering
Market saturation as installed base penetrates majority of US hospital MRI suites (estimated 13,000-14,000 MRI systems nationwide), limiting domestic growth to replacement cycles
Entry by large medical device incumbents (GE HealthCare, Siemens Healthineers, Philips) leveraging MRI equipment relationships to bundle compatible monitoring devices
Price compression if competitors introduce lower-cost MRI-safe alternatives, particularly in international markets with lower reimbursement
Dependence on direct sales model limits geographic reach versus competitors with established distribution networks
Minimal financial risk given zero debt and $40M+ cash position (estimated), but limited financial flexibility to fund M&A or accelerate international expansion without dilutive equity raises
Concentration risk with manufacturing in single Florida facility - supply chain disruption or quality issues could halt production
moderate - Hospital capital equipment budgets exhibit some cyclicality but are less discretionary than elective procedures. MRI suite construction and equipment upgrades correlate with healthcare system profitability and patient volumes. Economic downturns may delay hospital capital projects 6-12 months, but demographic aging and chronic disease prevalence provide secular tailwinds. Disposables revenue (10-15% of sales) is non-cyclical, tied to MRI scan volumes.
Rising rates create modest headwinds through two channels: (1) Hospital systems face higher borrowing costs for capital projects, potentially delaying MRI suite builds or equipment purchases; (2) IRMD's premium valuation (44x EV/EBITDA) compresses as risk-free rates rise and growth stocks de-rate. However, zero debt insulates the company from financing cost pressures. Rate cuts would support hospital capital spending and multiple expansion.
Minimal - Customer base is primarily investment-grade hospital systems and imaging centers with stable cash flows. IRMD maintains 6.6x current ratio with zero debt, eliminating refinancing risk. Credit market stress could delay hospital capital budgets but unlikely to create receivables issues given healthcare system creditworthiness.
growth - Investors pay 15x sales and 44x EBITDA for 14% revenue growth, betting on installed base expansion, international penetration, and operating leverage driving 20%+ earnings growth. Small-cap growth funds and healthcare specialists attracted to niche market dominance, asset-light model, and 24% ROE. Momentum investors drove 78% one-year return on earnings beats and margin expansion.
high - $1.3B market cap with limited float creates sharp price swings on quarterly results. Beta likely 1.3-1.5x given small-cap healthcare device exposure. Stock vulnerable to multiple compression if growth decelerates or large-cap competitor enters niche. Recent 45% six-month surge indicates momentum-driven volatility.
